Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Role of Pioglitazone Therapy in Management of Insulin Resistance Associated With Androgen Deprivation Therapy (ADT) in Patients With Prostate Cancer

NCT05098327 is registered in ClinicalTrials.gov with State University of New York at Buffalo as lead sponsor.

NCT NCT05098327
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05098327 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Role of Pioglitazone Therapy in Management of Insulin Resistance Associated With Androgen Deprivation Therapy (ADT) in Patients With Prostate Cancer
Lead sponsor
State University of New York at Buffalo
Phase
Phase 3
Overall status
Withdrawn
Start date
August 1, 2021
Completion date
March 31, 2023
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

androgen deficiency, diabetes mellitus, type 2, insulin resistance, prostate cancer